Main Category:
Medical Devices News
Article Date: 14 Aug 2006 - 20:00pm (PDT)
|
email this article |
printer friendly |
view or write opinions |
InterCure, Ltd., today announced the publication of
a peer-reviewed clinical overview of seven clinical
trials evaluating the efficacy of device-guided
breathing. The study's authors conclude that
RESPeRATE, an FDA-cleared over-the-counter
therapeutic device, is an effective
non-pharmacologic treatment option for treating
hypertension with no side effects.
The article, published in the General Medicine
Journal (
http://www.medscape.com/viewarticle/539099)
of Medscape (NASDAQ:WBMD), is authored by William J.
Elliott, MD, PhD, professor of Preventive Medicine,
Internal Medicine and Pharmacology at Rush Medical
College, Ill., and Joseph L. Izzo, Jr., MD,
professor of medicine and vice chair of Medical
Research at the University of Buffalo, N.Y.
The article confirms the body of evidence from seven
published clinical studies concluding that routine
use of RESPeRATE, either alone or as an adjunctive
treatment with lifestyle modifications or
prescription drugs, significantly lowered blood
pressure with no adverse side effects. The study
also reviews the physiological mechanism of action
of device-guided breathing.
A summary of the results of the seven studies shows
an average all-day reduction of 14/8 mm Hg within
four to six weeks of commencement of 15-minute-daily
treatments with RESPeRATE. The reduction in blood
pressure was consistent between studies, whether
measurements were taken in the home, 24-hour
ambulatory setting or physician's office. Larger
blood pressure reductions were seen in older
individuals and those with higher baseline readings,
regardless of whether they were also being treated
with prescription antihypertensive medications.
The authors summarize the patient populations for
whom device-guided breathing appears to be
beneficial: (1) prehypertensives and white-coat or
labile hypertensives who might benefit from reducing
stress and sympathetic activity; (2) patients with
isolated systolic hypertension; and (3) patients
with resistant hypertension (uncontrolled blood
pressure despite use of a diuretic and at least two
other medications at maximum approved doses).
"When I was first introduced to RESPeRATE, I was
skeptical, but after seven trials, the body of data
speaks for itself. I have seen first-hand that as
long as patients use the device regularly, blood
pressure is reduced, with no side effects," says Dr.
William Elliott, Rush Medical Center. "Controlling
hypertension requires a comprehensive approach, and
device-guided breathing provides an additional
effective therapeutic modality to offer our
patients."
More than 65 million Americans have high blood
pressure, and even with traditional treatment
methods of diet, exercise and medication, 70 percent
of that population is either unable to reach their
lower blood pressure goals or can't tolerate the
side effects of medications. Left untreated, high
blood pressure may lead to heart attack, stroke and
kidney or heart failure.
###
About RESPeRATE
RESPeRATEŽ is FDA-cleared for over-the-counter sale
and is the only medical device on the market
clinically proven to lower blood pressure through
paced breathing therapy. The device uses the body's
natural tendency to follow external rhythms,
interactively guiding the user to effortlessly
reduce breathing rate to a "therapeutic zone" of
less than 10 breaths per minute. The breathing
exercises with RESPeRATE relax the constricted
muscles surrounding the small blood vessels,
allowing the blood to flow more freely and yielding
a significant and lasting reduction of blood
pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, has become a
leader in the growing Personal Therapeutic Device
category. Its broadly patented "device-guided
breathing" technology platform enables a systematic
reduction in sympathetic outflow of the autonomous
nervous system. InterCure is successfully selling
the world's 1st hypertension treatment device,
RESPeRATE. With multiple published clinical trials,
regulatory approvals in most key markets (FDA
over-the-counter ("OTC") clearance, CE mark, Chinese
SDA, and others) and a renowned scientific advisory
board, RESPeRATE is rapidly becoming a part of the
standard of care for the treatment of hypertension.
(
http://www.intercure.com/,
http://www.resperate.com/)
Contact: Jane Hauser
Schwartz Communications
